Monday, June 22, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 554 of 1,261

  1. US 10023614

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  2. US 10022325

    Compositions and methods for the treatment of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  3. US 10023641

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  4. US 10023879

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  5. US 10023627

    Vascular endothelial growth factor fusion protein

    KOREA PRIME PHARM CO., LTD. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  6. US 10022352

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  7. US 10022382

    RNA polymerase I inhibitors and uses thereof

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  8. US 10023587

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  9. US 10023544

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  10. US 10022367

    Sustained-release buprenorphine solutions

    Indivior UK Limited · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  11. US 10022347

    Compositions and methods for diagnosis and treatment of metabolic syndrome

    United States of America as represented by the Secretary of the Air Force · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  12. US 10022364

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  13. US 10022375

    Methods and compositions for inhibition of polymerase

    BioCryst Pharmaceuticals, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  14. US 10022385

    Thermo-kinetic mixing for pharmaceutical applications

    The Board of Regents of the University of Texas System · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  15. US 10022456

    Reversibly masked polymers

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  16. US 10023916

    Markers of tumor cell response to anti-cancer therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  17. US 10022450

    Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

    The Regents of the University of California · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  18. US 10023569

    Methods of preparing inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  19. US 10023862

    Organic compositions to treat beta-catenin-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  20. US 10023848

    Immunogenic composition comprising Panton-Valentine Leukocidin (PVL) derived polypeptides

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  21. US 10023654

    Anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  22. US 10023650

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  23. US 10023644

    Antigen-binding proteins that activate the leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  24. US 10023642

    Anti-PDGFR-beta antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.